Publications by authors named "R Faroux"
Fluropyrimidine monotherapy is an option for some patients with inoperable metastatic colorectal cancer. Unlike bevacizumab, the addition of aflibercept, an antibody acting as an anti-angiogenic agent, has never been evaluated in this context. The aim of the study was to determine whether aflibercept could increase the efficacy of fluoropyrimidine monotherapy without increasing toxicity.
View Article and Find Full Text PDFPredictive value of vascular endothelial growth factor polymorphisms for maintenance bevacizumab efficacy in metastatic colorectal cancer: an ancillary study of the PRODIGE 9 phase III trial.
Ther Adv Med Oncol
December 2022
Background: Several studies have reported the impact of single nucleotide polymorphisms (SNPs) in vascular endothelial growth factor () pathway genes on the efficacy of bevacizumab in metastatic colorectal cancer (mCRC), but results are still inconsistent. The PRODIGE 9 phase III study compared bevacizumab maintenance observation alone after induction chemotherapy with FOLFIRI plus bevacizumab.
Objective: We evaluated the impact of SNPs of , VEGF receptors (), and hypoxia inducible factor-1α () on tumor control duration (TCD), overall survival (OS), progression-free survival (PFS), and duration of first chemotherapy free-intervals (CFI).
Article Synopsis
- The study aimed to compare the anatomical presentation and severity of colonic diverticulosis between African Caribbeans (AC) and Europeans (E) in a controlled study involving 274 patients with lower gastrointestinal hemorrhage in France.
- Results showed that AC patients had consistently poorer hemodynamic conditions and required more blood transfusions compared to E patients, with AC exhibiting a higher prevalence of pancolonic diverticulosis while E had left-sided diverticulosis.
- The findings suggest that genetic factors may play a larger role in the anatomical differences observed in diverticulosis between the two groups, rather than environmental influences or dietary habits.
Background: In case of contraindication or intolerance to fluoropyrimidines, raltitrexed is a validated alternative in metastatic colorectal cancer (mCRC), associated or not with oxaliplatin. Little is known about the outcomes of raltitrexed combined with irinotecan or targeted therapies.
Methods: This retrospective multicentre study enroled mCRC patients treated with first-line raltitrexed-based chemotherapy.
Antibody-dependent cellular cytotoxicity (ADCC) in the anti-tumor effect of cetuximab in metastatic colorectal cancer (mCRC) is only based on the impact of FcγRIIIA (CD16) polymorphisms as predictive of therapeutic response. However, nature, density and therapeutic impact of FcγRIIIA (CD16) effector cells in tumor remain poorly documented. Moreover, the inhibition of cetuximab-mediated ADCC induced by NK cells by the engagement of the new inhibitory CD94-NKG2A immune checkpoint has only been demonstrated .
View Article and Find Full Text PDF